News for Cosmo Pharmaceuticals N.V. (CMOPF)

Release Date: March 06, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Cosmo Pharmaceu

Cosmo Pharmaceuticals N.V. (CMOPF) Monday said that Glenmark had received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to market Winlevi in the United Kingdom.

Revenue: EUR136.2 million, up from EUR43.7 million last year.Healthtech Revenue: Increased from EUR6.4 million to EUR97.5 million, driven by a EUR100 million u

DRAFT REMUNERATION POLICY COSMO Pharmaceuticals N.V. REMUNERATION POLICY 1. Introduction This...

EXPLANATORY NOTES TO THE AGENDA OF THE EXTRAORDINARY GENERAL MEETING OF COSMO PHARMACEUTICALS N.V. ON FRIDAY 5 JULY 2024. Item 1: Opening of the EGM. ...

NOTIFICATION OF NUMBER OF OUTSTANDING SHARES AND VOTING RIGHTS As of June 6, 2024, COSMO Pharmaceuticals N.V. has issued 17,543,522 ordinary shares, of which...

Cosmo Pharmaceuticals N.V. today announced its final audited results for the financial year 2023. Financial highlights As previously announced when publishing preliminary...

Exploring the Dividend Performance and Sustainability of Cosmo Pharmaceuticals NV (CMOPF) Cosmo Pharmaceuticals NV (CMOPF) recently announced a dividend of $2 p

Cosmo Pharmaceuticals N.V. today announced that its shareholders approved all agenda items at today's annual general meeting of shareholders. A total of 7,417,916 ordinary shares in...

Dublin, Ireland - 29 April 2024: Cosmo Pharmaceuticals N.V. today announced that the company has been granted extension until 31 May 2024 to publish its 2023 annual report and to file such...

Cosmo Pharmaceuticals N.V. today announced the appointment of Giovanni Di Napoli as its new Chief Executive Officer, along with changes to its Board of Directors, at the upcoming Annual...

Cosmo Pharmaceuticals N.V. announces that Medtronic plc , a global leader in healthcare technology, presented at the Genius Summit 2024 the latest advancements in artificial intelligence for...

Mar 20, 2024 / 10:00AM GMTAlessandro Della Cha - Cosmo Pharmaceuticals N.V. - CEO & Executive Director Preliminary unaudited full-year 2023 results. Just a litt

Medtronic deal accounted in 2024, to inject USD 200m cash. FDA approval of GI Genius new enhanced operating system. New GI drug development...

/PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK) today released its 2023 interim results. Revenue in the first half of 2023 reached...

Cosmo Pharmaceuticals N.V. / Key word(s): Agreement Cosmo and Hyundai Pharm Announce Signing of License Agreement for Winlevi® in Korea 22.06.2023 / 06:15 GMT/BST Dublin, Ireland & Seoul, Korea – 22 ...

/PRNewswire/ -- The acne drugs market size is forecast to increase by USD 907.11 million from 2022 to 2027, at a CAGR of 3.46%, according to the recent market...

/PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK) today announced its 2022 annual results. In 2022, 3SBio's core biopharmaceutical...

/PRNewswire/ -- Hyphens Pharma International Limited (